Abstract

EE362 A Budget Impact Analysis of Pertuzumab, Trastuzumab, and Chemotherapy in the Neoadjuvant Setting for HER2-Positive High-Risk Early Breast Cancer Patients: Insights from the Tuscany Regional Health Care System Perspective

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call